Biotechnology, Pharmaceutical and Life Science Reports and Courses

Main Pages

Best Selling Products

BioNewsCast Press Release Distribution Service

Vaccine Technology 2009 Conference

Veterinary Diagnostics Markets

Practical Guide to Finding Partners in Pharma & Biotech, 2nd edition

Royalty Financing Agreements in Pharma, Biotech and Diagnostics

New Products

Attention Deficit Hyperactivity Disorder: Diagnosis and Treatment

Bioinformatics Market Potential

Biotechnology in the European Union; Trends, Investing & Country Profiles

China Pharmaceutical Industry: Analysis and Market Trends

European Generic Drug Market Potential

Global Biotechnology Markets Trends

Strategic Alliances in World Pharma and Biotech Markets

Understanding China's Chemical Industry

Understanding Genomics and Global Health Impacts

Understanding Pharmacogenomics

BioPortfolio | Datamonitor Reports | Forecast Insight: Depression - Generic induced brand erosion leads to market decline

Forecast Insight: Depression - Generic induced brand erosion leads to market decline

The depression market was valued at around $11.04 billion in 2007 across the seven major markets. Following marginal growth to 2011 ($12.01 billion), the market is forecast to decline in value through to 2017 ($9.81 billion) when brand erosion due to generic incursion affecting all major drug classes used to treat depression finally outweighs the success of reformulations and follow-on products.

This report gives a strategic analysis of the likely impact that recent events will have on the future depression market

Includes depression-specific sales forecasts for the key brands, generics, and pipeline agents in the seven major markets to 2017

Provides a global depression-market snapshot, and analysis of growth trends in key markets outside of the seven major pharmaceutical markets

Conclusions are supported by key opinion leader comment

Datamonitor has upgraded its depression-specific Abilify and Seroquel forecasts following positive clinical trial data in depression for both atypical antipsychotics, and the observation that regulatory approval of Abilify as an adjunct to antidepressants in depression resulted in an increase in the brand's quarterly sales growth rate.

Servier and Novartis's Valdoxan has emerged as the most promising pipeline depression drug following failure of several late-stage candidates. Prescribing for depression patients suffering from comorbid sleep disorders will drive sales over the forecast period.

Datamonitor forecasts moderate uptake of saredutant in refractory depression patients as an add-on therapy. While the drug failed to show efficacy as a monotherapy in clinical trials published over the last year, Sanofi-aventis is continuing to develop saredutant with two add-on therapy trials ongoing.

Quantify the current size of the global major depressive disorder market

Assess the impact of recent and anticipated events (patent expiries, new product launches, regulatory approval) on depression-specific brand sales

Understand the country-specific impact of key events in the major depressive disorder market during the forecast period 2008 to 2017

Publication: 39783
Library Code: DMHC2459
Type: Report
Format: PDF & DataPack
Pages: 90

Table of Contents
Price: $15,200.00 / €10,159.68

BioPortfolio uses RBS Worldpay Secure Server for credit card transactions